CeriBell (CBLL) announced that the U.S. Food and Drug Administration, FDA, has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device. This clearance further establishes the Ceribell System as an AI-powered brain monitoring platform technology, extending the benefits to a larger population of critically ill patients and providing additional information to assist in diagnosing patients at risk for both seizures and delirium.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell management to meet virtually with BTIG
- Ceribell Gains FDA Clearance for Seizure Detection Algorithm
- Ceribell’s Strategic Expansion and Growth Potential with FDA Clearance for Clarity Algorithm
- Ceribell, Inc.: Buy Rating Affirmed on Market Expansion and Technological Advancements
- Ceribell receives FDA 510(k) clearance for Clarity algorithm